Corporate supply chains are showing a "degree of complacency" about escalating risks from the Iran war, according to a new analysis that raises uncomfortable questions about whether businesses learned anything from COVID-19 disruptions.
The Guardian report suggests many companies have failed to implement the resilience measures they promised after pandemic-era chaos exposed critical vulnerabilities. Now, with the Strait of Hormuz blockaded and shipping lanes rerouted, those same vulnerabilities are resurfacing.
Remember 2021? Every corporate earnings call featured executives pledging to diversify suppliers, increase inventory buffers, and build redundancy into logistics networks. The commitment to "never again" was nearly universal. Three years later, the evidence suggests those promises were mostly talk.
The Iran crisis exposes specific weak points. Energy-intensive manufacturing faces rising costs as oil prices surge. Asian electronics supply chains dependent on Persian Gulf shipping confront delays and rerouting expenses. Agricultural commodities tied to Middle Eastern ports see volatility spike. These aren't exotic scenarios—they're predictable consequences of regional conflict.
Supply chain consultants interviewed for the Guardian piece express frustration. Companies prioritized short-term cost optimization over long-term resilience once immediate COVID pressures eased. Just-in-time inventory practices crept back. Single-source suppliers regained favor. The institutional memory proved remarkably short.
The financial incentives work against resilience. Building redundant capacity costs money and reduces margins. Maintaining larger inventories ties up capital. Diversifying suppliers requires management attention and relationship investment. Wall Street rewards efficiency, not hypothetical crisis preparedness.
Until a crisis hits. Then shareholders demand to know why leadership didn't anticipate the obvious. The pattern is exhausting and entirely predictable.
Some sectors have improved. Pharmaceutical companies manufacturing critical drugs have genuinely diversified production. are building new fabs outside traditional geographic concentrations. maintain larger chip inventories than pre-COVID. Progress exists, but it's uneven.
